Funded by the Baillet Latour Fund, SPECTAlung is an initiative within the framework of the research program of the EORTC in collaboration with ETOP. Created in 1962 by European cancer specialists, the EORTC is an international non-profit research organization governed by Belgian law whose mission is to improve survival and quality of life of patients with cancer. Engaged in research on thoracic malignancies, ETOP promotes the exchange of ideas and research in this field, sponsors and manages an increasing number of translational research projects and clinical trials to contribute to advance knowledge on thoracic cancer in general.

SPECTAlung stands for ‘Screening Patients with thoracic tumors for Efficient Clinical Trials Access’

SPECTAlung is the first ever European prospective fully annotated tumour samples Biobank and Biomarker analysis platform for genetic profiling of patients diagnosed with thoracic cancer.

This platform unique in its kind joins up clinical forces at a Pan-European level to develop personalized treatments based on the results of the tissue sampling analysis. Supported by a network of 18 main clinical centers with thoracic expertise in 12 countries, this initiative has the ultimate goal of enabling better access to treatment options.  SPECTAlung is expecting to enroll approximately 500 patients for the first year and  up to 1000 patients for the following years. To date, the EORTC is proud to announce that 77 patients have been enrolled since the official start of the biobank on 22 May 2015!

Thoracic cancer

Thoracic cancer comprehends various types of  cancers such as Lung cancer; Malignant Pleural Mesothelomia ; Thymic malignancies). (Source NCI)

More specifically, lung cancer is commonly classified as Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). (Source ACR)

Every year in Europe an estimated 409.900 persons of both genders are newly diagnosed with lung cancer and 353.500 will die of the disease in the same year. (Source EJC 2013)

Malignant Pleural Mesothelioma is a rare tumor with an incidence of 1.25/100.000 in the UK and 1.1/100.000 in Germany. Within the next 20 years the incidence is expected to double in many countries (Source: Annals Oncology 2010)

Thymic malignancies are rare tumors with a reported overall age adjusted incidence of 0.2/100.000 a year.

(Source: Annals Oncology 2010)

Central Biobank, Gustave Roussy Cancer Campus – Grand Paris (Villejuif, France)


Thierry Berghmans – Institute Jules Bordet (Brussels)
Johan Vansteenkiste – Institute KU Leuven (Leuven)
Jan Van Meerbeeck –  Universitair Ziekenhuis Antwerpen (Antwerpen


Meldgaard – Aarhus University Hospital (Aarhus)


Benjamin Besse – Gustave Roussy, Cancer Campus – Grand Paris (Villejuif)
Julien Mazieres – Hôpital Larrey (Toulouse)


Martin Reck – Center of Pneumology and Thoracic Surgery of Grosshansdorf (Grosshansdorf)


Steven Finn – St James Institute (Dublin)


Silvia Novello – University of Turin (Orbassano)
Andrea Ardizzoni  –  Policlinico S. Orsola-Malpighi (Bologna)


Egbert Smit – VU University Medical Center (Amsterdam)


Rafal Dziadziuszko – University of Gdansk (Gdansk)


Tanja Cufer – University Clinic Golnik (Golnik)


Enriqueta Felip – Vall d’Hebron University Hospital (Barcelona)
Luis Paz- Ares – Virgen del Rocio University Hospital (Sevilla)


Rolf Stahel – University Hospital of Zurich (Zurich)
Solange Peters – University of Lausanne (Lausanne)


United Kingdom
Sanjay Popat – Royal Marsden (Sutton)